Trilaciclib prior to chemotherapy in patients with metastatic triple-negative breast cancer: final efficacy and subgroup analysis from a randomized phase II study

Subgroup Analysis ◽

Triple Negative ◽

Phase Ii Study ◽

Randomized phase II study of sunitinib versus standard of care for patients with previously treated advanced triple-negative breast cancer

The Breast ◽

10.1016/j.breast.2013.07.037 ◽

2013 ◽

Vol 22 (5) ◽

pp. 650-656 ◽

Cited By ~ 41

Author(s):

Giuseppe Curigliano ◽

Xavier Pivot ◽

Javer Cortés ◽

Anthony Elias ◽

Rossano Cesari ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Triple Negative ◽

Phase Ii Study ◽

Standard Of Care ◽

Randomized Phase Ii ◽

Previously Treated

A Randomized Phase II Study of Anti-CSF-1 Monoclonal Antibody Lacnotuzumab (MCS110) Combined with Gemcitabine and Carboplatin in Advanced Triple Negative Breast Cancer

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-20-3955 ◽

2021 ◽

pp. clincanres.3955.2020

Author(s):

Sherko Kuemmel ◽

Mario Campone ◽

Delphine Loirat ◽

Rafael López López ◽

J. Thaddeus Beck ◽

...

Keyword(s):

Breast Cancer ◽

Monoclonal Antibody ◽

Phase Ii ◽

Triple Negative ◽

Phase Ii Study ◽

P5-19-04: Results of a Randomized Phase II Study Demonstrate Benefit of Platinum-Based Regimen in the First-Line Treatment of Triple Negative Breast Cancer (TNBC).

10.1158/0008-5472.sabcs11-p5-19-04 ◽

2011 ◽

Author(s):

Y Fan ◽

BH Xu ◽

P Yuan ◽

JY Wang ◽

F Ma ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Triple Negative ◽

Phase Ii Study ◽

Line Treatment ◽

First Line ◽

Randomized Phase Ii ◽

First Line Treatment

Abstract P6-12-02: A Randomized Phase II Study of Sunitinib vs. Standard of Care for Patients with Previously Treated Advanced Triple-Negative Breast Cancer

10.1158/0008-5472.sabcs10-p6-12-02 ◽

2010 ◽

Cited By ~ 4

Author(s):

G Curigliano ◽

X Pivot ◽

J Cortes ◽

A Elias ◽

R Cesari ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Triple Negative ◽

Phase Ii Study ◽

Standard Of Care ◽

Randomized Phase Ii ◽

Previously Treated

A randomized phase II study of peri-operative ipilimumab, nivolumab and cryoablation versus standard care in women with residual, early stage/resectable, triple negative breast cancer after standard-of-care neoadjuvant chemotherapy

Annals of Oncology ◽

10.1093/annonc/mdz240.111 ◽

2019 ◽

Vol 30 ◽

pp. v97

Author(s):

H.L. McArthur ◽

E.A. Comen ◽

Y. Bryce ◽

S.B. Solomon ◽

J.H.S. Leal ◽

...

Keyword(s):

Breast Cancer ◽

Neoadjuvant Chemotherapy ◽

Phase Ii ◽

Standard Care ◽

Triple Negative ◽

Phase Ii Study ◽

Early Stage ◽

Standard Of Care ◽

Final Results of a Randomized Phase II Study Demonstrating Efficacy and Safety of BSI-201, a Poly (ADP-Ribose) Polymerase (PARP) Inhibitor, in Combination with Gemcitabine/Carboplatin (G/C) in Metastatic Triple Negative Breast Cancer (TNBC).

10.1158/0008-5472.sabcs-09-3122 ◽

2009 ◽

Cited By ~ 16

Author(s):

J. O'Shaughnessy ◽

C. Osborne ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Triple Negative ◽

Phase Ii Study ◽

Parp Inhibitor ◽

Efficacy And Safety ◽

TBCRC030: A randomized, phase II study of preoperative cisplatin versus paclitaxel in patients (pts) with BRCA1/2-proficient triple-negative breast cancer (TNBC)—Evaluating the homologous recombination deficiency (HRD) biomarker.

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.15_suppl.tps1145 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. TPS1145-TPS1145

Author(s):

Erica L. Mayer ◽

Ines Vaz-Luis ◽

Andrea L. Richardson ◽

Charles M. Perou ◽

Nadine M. Tung ◽

...

Keyword(s):

Breast Cancer ◽

Homologous Recombination ◽

Phase Ii ◽

Triple Negative ◽

Phase Ii Study ◽

Homologous Recombination Deficiency ◽

123MO BARBICAN: A randomized, phase II study to determine the contribution of ipatasertib to neoadjuvant chemotherapy plus atezolizumab in women with triple-negative breast cancer

Annals of Oncology ◽

10.1016/j.annonc.2021.08.404 ◽

2021 ◽

Vol 32 ◽

pp. S411-S412

Author(s):

P. Schmid ◽

F.J. Salvador Bofill ◽

B. Bermejo ◽

M. Phillips ◽

D. Wheatley ◽

...

Keyword(s):

Breast Cancer ◽

Neoadjuvant Chemotherapy ◽

Phase Ii ◽

Triple Negative ◽

Phase Ii Study ◽

A randomized phase II study to investigate the addition of PD-L1 antibody MEDI4673 (durvalumab) to a taxane-anthracycline containing chemotherapy in triple negative breast cancer (GeparNuevo)

Annals of Oncology ◽

10.1093/annonc/mdw364.77 ◽

2016 ◽

Vol 27 ◽

pp. vi67

Author(s):

S. Loibl ◽

A. Schneeweiss ◽

N. Burchardi ◽

J.-U. Blohmer ◽

C. Hanusch ◽

...

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Triple Negative ◽

Phase Ii Study ◽

A Prospective, Belgian Multi-center, Single-arm, Phase II Study of Neoadjuvant Weekly Paclitaxel and Carboplatin Followed by Dose Dense Epirubicin and Cyclophosphamide in Stage II and III Triple Negative Breast Cancer

Case Medical Research ◽

10.31525/ct1-nct04224922 ◽

2020 ◽

Author(s):

Keyword(s):

Breast Cancer ◽

Phase Ii ◽

Triple Negative ◽

Phase Ii Study ◽

Stage Ii ◽

Weekly Paclitaxel ◽

Dose Dense